人凝血酶原复合物治疗乙型血友病的有效性和安全性评价

打开文本图片集

【摘要】目的：探讨人凝血酶原复合物治疗乙型血友病临床效果及用药安全性。方法：抽取我院2019年3月—2022年3月收治的乙型血友病患者20例为研究对象，所有患者均接受人凝血酶原复合物治疗，观察患者凝血因子活性值及凝血功能变化情况，并评估两组治疗效果及安全性。结果：①20例患者治疗30min后凝血因子Ⅱ、Ⅶ、Ⅸ、Ⅹ活性值显著高于治疗前（P

【关键词】乙型血友病；人凝血酶原复合物；疗效；安全性

Evaluation of the efficacy and safety of human prothrombin complex in the treatment of hemophilia B

LONG Haiying， ZHANG Jun

The Second Affiliated Hospital of Guizhou Medical University， Kaili， Guizhou 556000， China

【Abstract】Objective： To explore the clinical efficacy and medication safety of human prothrombin complex in the treatment of hemophilia B. Methods： Twenty patients with hemophilia B admitted to our hospital from March 2019 to March 2022 were selected as the study subjects. All patients received treatment with human prothrombin complex， and the activity values of coagulation factors and changes in coagulation function were observed. The treatment effects and safety of the two groups were evaluated. Results： ① After 30 minutes of treatment， the activity values of coagulation factors Ⅱ、Ⅶ、Ⅸ， and Ⅹin 20 patients were significantly higher than before treatment（P

【Key Words】Hemophilia B； Human prothrombin complex； Efficacy； Security

因缺乏凝血因子IX造成的凝血障碍性疾病，称为乙型血友病[1]。（剩余4575字）